Advanced search
Publication Cover
Cancer Investigation Volume 20, 2002 - Issue 2
Submit an article Journal homepage
64
Views
11
CrossRef citations to date
0
Altmetric
Original

A Phase II Study of CI-980 in Previously Untreated Extensive Small Cell Lung Cancer: An Ohio State University Phase II Research Consortium Study

Jason P. Thomas Division of Hematology/Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, U.S.A.
, M.D.,
Timothy Moore Grant Medical Center, Columbus, Ohio, U.S.A.
, M.D.,
Eric H. Kraut Division of Hematology/Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, U.S.A.
, M.D.,
Stanley P. Balcerzak Division of Hematology/Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, U.S.A.
, M.D.,
Sharon Galloway Division of Hematology/Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, U.S.A.
&
Dale D. Vandre Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, U.S.A.
, Ph.D.
Pages 192-198 | Published online: 04 Sep 2002

REFERENCES

  • Landis S.H., Marray T., Bolden S., , et al. Cancer Statistics, 1998. Cancer J. Clin. (CA) 1998; 48: 6–29
  • Sorenson M., Lassen U., Hansen H.H. Current Therapy of Small Cell Lung Cancer. Curr. Opin. Oncol. 1998; 10: 133–138
  • Souhami R.L., Law K. Longevity in Small Cell Lung Cancer: A Report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br. J. Cancer 1990; 61: 6840589
  • Bowdon B.J., Waud W.R., Wheeler G.P., , et al. Comparison of 1,2-Dihydropyrido[3,4-b]Pyrazines (1-Deaza-7,8-Dihydropteridines) with Several Other Inhibitors of Mitosis. Cancer Res. 1987; 47: 1621–1626
  • Waud W.R., Leopold W.R., Elliott W.L., , et al. Antitumor Activity of Ethyl 5-Amino-1,2-Dihydro-2-Methyl-2-Phenylpyrido[3,4-b]Pyrazin-7-yl Carbamate 2-Hydroxyethanesulfonate Hydrate (NSC 370147) Against Selected Tumor Cells and in Mice. Cancer Res. 1990; 50(11)3239–3244
  • Waud W.R., Harrison S.D., Jr., Temple C.G., , et al. Antitumor Drug Cross Resistance in a Murine P388 Leukemia Resistant to Ethyl 5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido[3,4-b]Pyrazin-78-yl Carbamate 2-Hydroxyethanesulfonate Hydrate (NSC 370147). Cancer Chemother. Pharmacol. 1992; 29: 190–194
  • Sklarin N.T., Lathia C.D., Benson L., , et al. A Phase I Trial and Pharmacokinetic Evaluation of CI-980 in Patients with Advanced Solid Tumors. Invest. New Drugs 1997; 15(3)235–246
  • Rowinsky E.K., Long G.S., Noe D.A., , et al. Phase I and Pharmocological Study of CI-980, A Novel Synthetic Antimicrotubule Agent. Clin. Cancer Res. 1997; 3(3)401–406
  • Oken M.M., Creech R.H., Tormey D.C., , et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5(6)649–655
  • Ding M., Robinson J.M., Behrens B.C., , et al. The Microtubule Skeleton in Human Phagocytic Leukocytes is a Very Dynamic Structure. Eur. J. Cell Biol. 1996; 66(3)234–245
  • Murrah N., Shah A., Osaba D., , et al. Intensive Weekly Chemotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer. J. Clin. Oncol. 1991; 9: 1632–1638
  • Miles D.W., Earl H.M., Souhami R.L., , et al. Intensive Weekly Chemotherapy for Good-Prognosis Patients with Small Cell Lung Cancer. J. Clin. Oncol. 1991; 9: 280–285
  • Barton-Burke M. Gemcitabine: A Pharmocological and Clinical Review. Cancer Nurs. 1999; 22(2)176–183
  • Ormond D., Spencer C.M. Topotecan: A Review of Its Efficacy in Small Cell Lung Cancer. Drugs 1999; 58(3)5330551
  • Evans W.K., Shepherd F.A., Feld R., , et al. VP-16 and Cisplatin as First-Line Therapy for Small Cell Lung Cancer. J. Clin. Oncol. 1985; 3: 1471–1477
  • Lownebraun S., Birch S., Buchanan R., , et al. Combination Chemotherapy in Small Cell Lung Carcinoma: A Randomized Study of Two Intensive Regimens. Cancer 1984; 54: 2344–2350
  • Pazdur R., Meyers C., Diaz-Canton E., , et al. Phase II Trial of Intravenous CI-980 (NSC 370147) in Patients with Metastatic Colorectal Carcinoma. Model for Prospective Evaluation of Neurotoxicity. Am. J. Clin. Oncol. 1997; 20(6)573–576
  • Patel S.R., Burgess M.A., Papadopolous N.E., , et al. Phase II Study of CI-980 (NSC 635370) in Patients with Previously Treated Advanced Soft-Tissue Sarcomas. Invest. New Drugs 1998; 16(1)87–92
  • Kudelka A.P., Hasenburg A., Verschraegen C.F., , et al. Phase II Study of i.v. CI-980 in Patients with Advanced Platinum Refractory Epithelial Ovarian Carcinoma. Anticancer Drugs 1998; 9(5)405–409

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.